Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BEBT-908 Combined with Standard Regimens in Relapsed/Refractory DLBCL
NCT06164327Phase 1Recruiting
- Sponsor
- BeBetter Med
- Start
- Dec 2023
- Primary completion
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of ifupinostat in diffuse large B-cell lymphoma (DLBCL) (5 arms), sponsored by BeBetter Med. Primary endpoints: Objective Response Rate at 24 months and Adverse Events. Started Dec 2023; status: recruiting.
02
Drugs
ifupinostat
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT06164327.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06164327.